EU Regulators Back AstraZeneca's Klygefa for Myasthenia Gravis
AZN is trading near its 52-week low of $146.1 (14% above the low).
Summary
AstraZeneca's Klygefa received a positive CHMP opinion for EU approval in generalized myasthenia gravis, backed by Phase III data showing significant symptom improvement with once-weekly subcutaneous dosing.
Key Events · Product Development and Regulatory · AZN
-
CHMP Positive Opinion for Klygefa
EU regulators recommended approval of Klygefa (gefurulimab) as add-on therapy for AChR antibody-positive generalized myasthenia gravis in adults.
-
PREVAIL Phase III Efficacy
Klygefa met its primary endpoint with a -1.6 point MG-ADL improvement versus placebo (95% CI -2.4 to -0.8, p<0.0001), with clinically meaningful benefit seen as early as week one.
-
First-in-Class Positioning
If approved, Klygefa would be the first and only dual-binding nanobody C5 inhibitor for gMG in the EU, offering once-weekly subcutaneous self-administration via autoinjector.
-
Regulatory Momentum
Klygefa is already approved in Japan and other countries; submissions are under review in the US, China, and additional markets.
Analysis · AZN · Life Sciences
A positive CHMP opinion brings Klygefa one step closer to EU approval in generalized myasthenia gravis, a rare disease market where AstraZeneca's Alexion unit already holds a strong franchise. The PREVAIL data show a statistically significant but modest MG-ADL improvement of -1.6 points versus placebo, with once-weekly subcutaneous dosing as the key differentiator. If approved, Klygefa would be the first dual-binding nanobody C5 inhibitor in the EU for this indication, expanding Alexion's complement-inhibitor portfolio beyond Soliris and Ultomiris.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 34.9% of the 999 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $167.05 on NYSE in the Life Sciences sector, with a market capitalization of approximately $257.6B. The 52-week trading range was $146.10 to $212.71. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.